INTRODUCTION
Lower gastrointestinal cancers have transformed from deadly diseases to survivable, and often curable, illnesses with advancements in therapies and earlier detection of tumors. Colorectal cancers are the third most commonly diagnosed cancers in the United States, affecting approximately 4.5% of adults during their lifetime. Anal cancers occur less often, being diagnosed in approximately 0.2% of men and women. Although the incidence of colorectal cancers has decreased over the past 30 years, the incidence of anal cancers has increased. Five-year survival rates for all stages of disease have increased over the same time frame to 65.1% and 66.4% for colorectal and anal cancer, respectively. 1 Consequently, the number of survivors living after a diagnosis of lower gastrointestinal cancer has become quite significant. Most recently, it has been estimated that there are more than 1.4 million individuals living in the United States with a previous diagnosis of colorectal cancer. tools and have been derived from select groups, including clinical trials or small-scale retrospective series; however, recent studies are increasingly using population-based surveys. [9] [10] [11] The current study examines a convenience sample from colorectal and anal cancer survivors who voluntarily used a publically available, Internet-based tool to create survivorship care plans (SCPs). The tool surveys survivors or proxies about disease course, treatment plan, and perceived side effects and, in turn, provides information about the survivor's disease, side effects, and treatment based on their responses. To the best of our knowledge, this tool represents a unique source of PROs. We present patient-reported data from lower gastrointestinal cancer survivors or their proxies to describe the sequelae associated with these cancers and their treatments as well as perceptions of the tool itself.
MATERIALS AND METHODS

SCPs
An Internet-based tool for the creation of SCPs designed by a team of oncology nurses and physicians at the Abramson Cancer Center of the University of Pennsylvania was made publically available through OncoLink (www.oncolink.org. Accessed December 21, 2016) in 2007. For a portion of the time during which data were gathered for this study, the care plan was also available as the LIVESTRONG Care Plan (available at www.livestrongcareplan.org. Accessed December 21, 2016). It can now be found at http://www.oncolink.org/oncolife. Accessed December 21, 2016. The resource allows patients, family members, or health care providers to input data regarding demographics, diagnosis, treatment course, and PROs to provide individualized, comprehensive health care recommendations for future care. 12 These recommendations are evidence-based or consensus-based wherever possible and are in accordance with guidelines provided by the National Cancer Institute and the American Society of Clinical Oncology. In areas where formalized guidelines are not available, the care plan's recommendations are based on our institution's own practice and with guidance from leaders in the field of survivorship medicine.
Since its creation, the tool has undergone several revisions and modifications to include questions regarding LLTEs that are customized to the survivor's specific treatments and/or primary cancer diagnosis. These responses also are used to prioritize content in the care plan. A 5-question, 1-page user-satisfaction survey was added through an optional link accessible upon receipt of the care plan.
The care plan tool is publically accessible through OncoLink (www.oncolink.org, www.oncolife.org. Accessed December 21, 2016), allowing users to find it independently or be made aware by their health care provider. Upon completion of the tool's queries, the care plan is generated and received in PDF format.
Data Collection and Analysis
All users were first queried regarding demographic and treatment information. They were then queried about outcomes customized to their prior responses with the intent of targeting LLTEs for which the individual survivor was at the highest risk. Given the adaptive nature of this questioning, not all users are offered every question regarding LLTEs. Answer choices were typically formatted as "yes," "no," or "I don't know," unless otherwise specified.
Care plan completion rates for the overall user population demonstrate that 75% of users who start page 1 move forward to page 2; and, of those, 100% complete the entire questionnaire. Only fully completed care plans were included in this analysis. Demographic, treatment, and toxicity data were reviewed along with follow-up survey responses. Chi-square tests of independence were used to assess the statistical significance of comparisons.
Institutional Review Board approval was obtained before any study proceedings. For this study, data were obtained from the survivor user database for all patients with colon, rectal, and anal cancer since the launch of the seventh version, which includes questions regarding LLTEs. Survey respondents from May 2010 to October 2014 were included in this study.
RESULTS
Demographics
Care plans created for colon, rectal, and anal cancer survivors were included as part of this analysis (n 5 1129), and 792 (70.2%), 218 (19.3%), and 119 (10%) users responded per cancer site, respectively. Slightly more than one-half of survivors were women (57.9%). The median age at diagnosis was 51 years (mean, 51.5 years; range, 18-94 years), and the median age at time of survey response was 54 years (mean, 53.9 years; range, 18-96 years). The median time from diagnosis to reporting was 1 year (mean, 2.4 years; range, 0-46 years). With regard to race, 80.8% survivors were Caucasian, and there were small representations of African American and Asian survivors (5.5% and 5.7%, respectively). Approximately one-half of survivors had a college degree or greater (47%). Survivors most often lived in a suburban (44%) or urban (34.5%) environment, and 72.6% commuted < 20 miles to their treatment center (n 5 820). Demographic data are summarized in Table 1 .
Treatment History
Nonuniversity-based hospital cancer centers offered care to 47.3% of survivors, and university-based cancer centers treated 26.5%. In total, 60.4% of colon cancer survivors underwent surgery and received chemotherapy, 72% of rectal cancer survivors underwent surgery and received both chemotherapy and radiation, and 56.3% of anal cancer survivors received both chemotherapy and radiation. Treatment history by cancer site is further summarized in Table 2 .
Most patients' oncologic care was managed exclusively by an oncologist or in combination with a primary care provider (47.8% and 35%, respectively). Few survivors indicated that they were offered an SCP or a treatment summary before their use of the care plan tool (10.5% and 20.6%, respectively). Of 830 responders, 18.9% (n 5 157) described themselves as living with metastatic disease, and 6.8% (n 5 56) were experiencing a recurrence after completing treatment.
LLTEs
More than one-half of patients reported fatigue (56.1%) and neuropathy in hands and/or feet (64.8%). Cognitive changes also reportedly were common, with 48.6% (444 of 914 survivors) reporting the presence of symptoms. LLTEs related to gastrointestinal effects, sexual dysfunction, and radiation-induced dermatologic effects were also reported frequently and are further detailed in Figure 1 .
LLTEs were compared between primary tumor sites, and age-adjusted rates are reported in Figure 2 . Both anal cancer and rectal cancer male survivors noted a higher prevalence of erectile dysfunction (36% and 32.6%, respectively) than male colon cancer survivors (17.9%; P < .01). Female anal cancer survivors also experienced an increased prevalence of sexual dysfunction, with 62% reporting sexual changes compared with 36.8% and 45.2% of female colon and rectal cancer survivors (P < .01), respectively. Anal cancer survivors also disproportionately reported radiation-induced dermatologic effects, including changes in skin color and/or texture (P < .01) and loss of flexibility at the radiated site (P < .01), at nearly twice the rate of those reported by colorectal cancer survivors. Significant differences between sites were also observed for radiation colitis (P 5 .01), bowel strictures or obstruction (P 5 .04), neuropathy (P 5 .04), and chronic changes to skin and nails (P < .01).
Perceived effects were analyzed by treatment modality and adjusted for age and cancer site (Fig. 3a,b) . Chronic changes in bowel patterns appeared to be more prevalent in the trimodality setting (55.9%) compared with surgery alone (30.7%; P < .01) or chemotherapy plus surgery (41.5%; P < .01). Sexual dysfunction in both men and women reportedly was more common in the trimodality setting (35.2% and 50.2%, respectively) than chemotherapy plus surgery (13.7% and 30%, respectively; P < .01 for both). Fatigue was also reported more frequently by survivors who received trimodality treatment (57.9%) than by those who received chemotherapy and radiotherapy (42%; P < .01) or chemotherapy and surgery (45.5%; P < .01). It is noteworthy that survivors who had a permanent colostomy (n 5 150) more commonly reported specific late effects than those without a colostomy. These included erectile dysfunction (34.8% vs 10.7%; P < .01) and diagnoses of bowel strictures or obstruction (32.9% vs 17.6%; P < .01).
Reported side effects were further examined based on the time since diagnosis and are described in Figure 4 . Survivors at > 5 years from diagnosis (n 5 177) were compared with survivors at 2 years but < 5 years from diagnosis (n 5 274) and at < 2 years from diagnosis (n 5 678). The 2-year threshold was selected because these users' reported effects likely reflected current effects rather than LLTEs of treatment. The P values provided in Figure 4 are derived from chi-square analysis using a 2 3 3 contingency table. Reported effects that significantly increased over time from diagnosis included erectile dysfunction (P < .01), bowel strictures or obstruction (P < .01), radiation colitis (P < .01), loss of flexibility to the radiated area (P 5 .03), and bladder fibrosis (P < .01). Maximum symptom prevalence for female-related sexual dysfunction and changes in bowel patterns was experienced between 2 and 5 years from diagnosis. Fatigue and neuropathy appeared to decrease over time from diagnosis, but the difference did not meet statistical significance.
Finally, the association of academic versus nonacademic treatment centers with patient-reported LLTEs were examined. Nonacademic treatment centers included both nonuniversity-affiliated cancer centers and private physicians' offices; survivors who reported receiving treatment at a combination of academic and nonacademic institutions were excluded from this analysis. There were no differences in race (P 5 .39), diagnosis age (P 5 .48), education (P 5 .35), or distance to treatment center (P 5 .25); however, a greater proportion of survivors living in urban centers received treatment at academic centers (P < .01). Survivors who received treatment at nonacademic centers (n 5 687) reported female-related sexual changes, cognitive changes, fatigue, and neuropathy at an increased rate compared with those who were treated at academic centers (n 5 299). Figure 5 further details these results.
Follow-Up Survey
In total, 228 users (20.2%) completed the brief 5-question survey at the time of SCP receipt. Demographic details of survey responders were compared with those of nonresponders using 2-sample t tests for continuous variables and chi-square tests of independence for categorical variables. Survey responders were represented by a greater proportion of survivors having received some college education or more (21.9% vs 13%; P 5 .03), living-> 20 miles from their cancer center (32.9% vs 26%; P 5 04), not receiving care at an academic center (20.5% vs 15.4%; P 5 .06), and female sex (63.6% vs 56.5%; P 5 .05) compared with nonresponders. The responses are detailed in Table 3 .
DISCUSSION
PROs from 1129 survivors of colorectal and anal cancer and their proxies demonstrate that it is feasible to obtain information on cancer treatment, self-reported symptoms, and response to receipt of SCPs through an Internet-based program. LLTEs reported by users generally relate to neuropathy, neurocognitive decline, changes in gastrointestinal function, urogenital and sexual dysfunction, and dermatologic effects and are consistent with previous reports. [4] [5] [6] [7] [8] [9] [10] Reported together, as done in this study, these observations give a broad perspective with regard to the side effects experienced by colorectal and anal cancer survivors as a population. It is important for Figure 2 . The age-adjusted prevalence of perceived late effects is illustrated by cancer site Figure 3 . The age-adjusted and site-adjusted prevalence of perceived late effects is illustrated according to lower gastrointestinal cancer survivors who received (a) trimodality treatment versus chemotherapy and surgery or (b) trimodality treatment versus chemotherapy and radiotherapy.
physicians-whether oncologic specialists or primary care providers-to recognize this spectrum of effects that a patient may experience during survivorship. In addition, the incorporation of PROs enables care providers to be more aware of survivorship issues that have not been captured by traditional physician-reported effects. For example, oncologists are particularly vigilant about tracking dose-related toxicities while following survivors of lower gastrointestinal cancers, including chronic neuropathy, alterations in bowel patterns, and radiation-induced complications. However, our report suggests an equal representation of fatigue, cognitive changes, and sexual dysfunction within these survivors-such symptoms that are not traditionally considered sequelae of treatment but certainly have an impact on quality of life.
Perceived effects were broken down by primary cancer site, revealing differences within each subpopulation. Notably, the PROs presented in this cohort of anal cancer survivors are among the few to be published and highlight the paucity of anal cancer survivorship literature. 8 In our findings, anal cancer survivors experienced side effects similar to those reported in other lower gastrointestinal cancers, although with increased frequency of sexual dysfunction and radiation-induced skin changes. The increased frequency of these side effects likely reflects the finding that 56.3% (n 5 67) and 40% (n 5 44) of our anal cancer survivors reported treatment with chemotherapy plus radiation or a trimodality approach, respectively. Awareness of these reported effects can help providers anticipate and, in some cases, minimize morbidity in this population. For example, it is important to counsel patients on the late effects of sexual function before treatment and for physicians to be attentive to those patients who wish to discuss sexual health during follow-up. Not only are interventions available, but they are simple and effective; these include lubricants, creams, and dilators for women and phosphodiesterase inhibitors and/or testosterone replacement in men. 13 Furthermore, our data highlight the finding that, to minimize both acute and late radiation-induced skin effects, prophylactic skin care is especially paramount for patients with anal cancer who are undergoing treatment.
On a similar note, we also explored the differences between treatment modalities. Perhaps not unexpectedly, the patients who received the combination of chemotherapy, surgery, and radiotherapy had a greater prevalence of many LLTEs, including chronic changes in bowel patterns, sexual dysfunction, and fatigue. The exception to this was radiation-induced dermatologic complaints, including loss of flexibility and changes in the color/texture of skin in the radiated area: these were reported less frequently by survivors who received all 3 treatment modalities. This finding runs counter to expectations and may be explained by potential contamination in the data if users included salvage treatments in their report, thus adding to the count of trimodality recipients while not incurring the known toxicities of these challenging treatment regimens. The increased prevalence of erectile dysfunction in survivors with a permanent colostomy is likely related to surgical resection of low-lying tumor and manipulation around the prostate.
Our data indicate that many side effects become more prevalent as the survivorship population moves further from diagnosis. This is particularly interesting, because recently diagnosed survivors may have been expected to report the current effects of active treatment, providing a confounding mechanism that would overestimate the effect burden in early survivorship. Previous studies have observed similar patterns in which cancer complications-especially those related to bowel patterns and sexual dysfunction-may persist for years after diagnosis. 5, 9 These observations emphasize the importance of continued counseling on chronic effects and anticipation of new-onset late effects as patients move forward in survivorship.
Survivors who were treated at academic centers appeared to report LLTEs at a decreased rate compared with those who were treated at nonacademic institutions, most notably with regard to cognitive changes, fatigue, neuropathy, and female sexual dysfunction. Conventional wisdom assumes that treatment at academic hospitals is associated with improved patient outcomes. The reasons for this assumption are myriad: these high-volume institutions are experienced in delivering the standard-of-care while also pushing the envelope with innovative therapies, use multidisciplinary treatment teams in most patient cases, and are increasingly integrating survivorship care clinics into their practice. Formal evidence regarding the association between institutional academic status and PROs is extremely limited. Because PROs are more frequently integrated into outcomes research and clinical care decisions, further investigation of the differences between academic versus nonacademic institutions is needed. Furthermore, the information obtained from our survivorship tool did not include details regarding the type of care model (ie, community-based, disease-specific cancer clinic, comprehensive survivorship program, etc) at which survivors received treatment, although our survey results suggest that only a small number of respondents (13.2%; n 5 30) were aware that their cancer center had an established survivorship program. A single study points toward improved symptom burden and quality of life when patients were followed at an academic institution with a survivorship care clinic. However, that study was restricted to a select disease site, a specific intervention, and a single institution, thus limiting generalizability of the findings.
14 In addition to providing information to the survivor, these care plans are also intended to facilitate provider-to-provider communication. A fair majority of our users (69.4%) indicated that they would share the health care provider summary with their health care team. A recent survey of primary care providers who received personalized care plans for patients enrolled on a survivorship clinical trial suggested that plans were viewed as useful for coordinating care and making clinical decisions. 15 These data indicate that SCPs are not extraneous to the survivor's health care management and in fact fulfill a need within comprehensive survivorship health care as originally identified in the Institute of Medicine's recommendations.
Although our survey assessed the users' immediate response to receipt of their SCP, it was not designed to determine whether these initial feelings translated into changes in health care communication or use. Some studies have demonstrated that SCPs improve communication between health care teams and survivors, influence greater lifestyle changes, increase follow-up rates, and improve self-perceived health status. 16, 17 Reports on the association of SCPs and health care communication/use have not been globally positive, however. A randomized trial in which 1 treatment arm received SCPs versus usual care delivery demonstrated that those survivors with care plans-although they had received more information on their illness-were more concerned about their illness, experienced more symptoms, and reported more cancerrelated contact with the health system. 18 That study was unable to clarify whether these reactions resulted from proactive management of survivorship-related issues of which SCPs had made them more aware. Further research is needed to help characterize the impact of SCPs on illness perception and efficacy of health care use.
SCPs plans are delivered in a variety of formats; some cancer centers may provide institution-specific documents, whereas others documents are publically available, including those provided by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, Memorial Sloan Kettering Cancer Center, and Journey Forward. The OncoLink SCP tool-formerly available through the LIVESTRONG Foundation-was the first Internet-based tool made available and remains unique in its adaptive functionality, which allows customized plans for each survivor's diagnosis and treatment course. Furthermore, to the best of our knowledge, it is the only tool from which PROs have been published. These PROs obtained through an Internet-based tool are powerful and also reveal an often overlooked component of survivorship, yet they do come with limitations. Several selection biases may be present within our sample. A volunteer effect could be observed, because the survivors who experience greater illness-related symptomatology also may have had more motivation to seek survivorship support. Another selection bias may be reflected in the finding that respondents participated through an Internet-based program. Previous studies have demonstrated that Caucasian patients with cancer are more likely to use the Internet to seek information about their diagnosis than patients of other races. In addition to racial differences, investigators have demonstrated that Internet users who are younger, more educated, of a higher socioeconomic class, who receive care at an academic hospital setting, and who self-report worse health status are more likely to access the Internet to obtain medical information. 19, 20 Our population was disproportionately Caucasian, female, and younger compared with the reported demographic composition of all patients with lower gastrointestinal cancers 1 ; as such, the generalization of these results must applied with healthy skepticism. Improving access to SCP tools could increase the generalizability of future reports by querying a more representative population. With the Commission on Cancer's mandate that every cancer patient should receive an SCP, which was implemented in 2015-past the date of our population's responses-future reports using our data source will likely reflect a more representative sample.
Given the anonymous nature of this reporting system, user profiles cannot be linked with medical records. This limits the ability to verify details of their cancer diagnosis and treatment history, which dictate the adaptive querying of symptoms. Inaccuracies in the reporting of these initial details could lead to failure in querying the appropriate population about the appropriate symptoms. Patient-reported treatment courses may include salvage treatments in addition to the initial treatment course and may explain some findings, such as high use of trimodality therapy in anal cancer. Without verification from medical records that, in fact, trimodality cases are not capturing multiple courses of treatment, comparisons between treatment modalities may be biased toward nonsignificance. Anonymous profiles also prohibit correlation of PROs with physician-reported measures.
This tool does not quantify the severity of symptoms, because they are currently reported in categorical variables ("yes," "no," or "I don't know"). Furthermore, patients are not queried about how their symptoms impact quality of life, an outcome often followed in survivorship research and clinical practice. Finally, the efficacy and application of SCPs are still unclear. Research is ongoing to assess the impact of SCPs on quality of life, survival, and other outcomes.
Herein, we report on the use of an Internet-based tool in lower gastrointestinal cancer survivors, including survivors of colon, rectal, and anal cancers. Our data indicate that these survivors face a wide spectrum of symptoms, including neurocognitive decline, changes in gastrointestinal function, urogenital and sexual dysfunction, and dermatologic effects. This information can be used in counseling at the time of diagnosis and around treatment decisions. Equally important is its application to survivorship care regarding anticipation of and proactive response to illness-related and treatment-related sequelae. Furthermore, early evidence suggests that survivors who receive treatment at academic centers experience a lesser burden of LLTEs. Finally, our users indicate a strong intent to share SCPs with their health care providers, which suggests an opportunity to improve survivorship-related communication and coordination of care. Further research is needed to elucidate these outcomes.
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